6.
Agrawal B, Nath A, Glynn Jr T, Velazco D, Garnett Jr R
. Unusual problems in breast cancer and a rare lung cancer case. Case 3. Simultaneous and synchronous bilateral inflammatory breast cancer. J Clin Oncol. 2003; 21(11):2218-20.
DOI: 10.1200/JCO.2003.11.505.
View
7.
Hance K, Anderson W, Devesa S, Young H, Levine P
. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst. 2005; 97(13):966-75.
PMC: 2844937.
DOI: 10.1093/jnci/dji172.
View
8.
Masannat Y, Peter M, Turton P, Shaaban A
. Case report of bilateral inflammatory breast cancer. Eur J Cancer Care (Engl). 2009; 19(4):558-60.
DOI: 10.1111/j.1365-2354.2009.01075.x.
View
9.
Kupstas A, Hoskin T, Day C, Boughey J, Habermann E, Hieken T
. Biological subtype, treatment response and outcomes in inflammatory breast cancer using data from the National Cancer Database. Br J Surg. 2020; 107(8):1033-1041.
DOI: 10.1002/bjs.11469.
View
10.
. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet. 2019; 393(10179):1440-1452.
PMC: 6451189.
DOI: 10.1016/S0140-6736(18)33137-4.
View
11.
Bertucci F, Finetti P, Colpaert C, Mamessier E, Parizel M, Dirix L
. PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget. 2015; 6(15):13506-19.
PMC: 4537030.
DOI: 10.18632/oncotarget.3642.
View
12.
Fernandez S, Robertson F, Pei J, Aburto-Chumpitaz L, Mu Z, Chu K
. Inflammatory breast cancer (IBC): clues for targeted therapies. Breast Cancer Res Treat. 2013; 140(1):23-33.
PMC: 4273486.
DOI: 10.1007/s10549-013-2600-4.
View
13.
Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F
. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013; 31(7):860-7.
DOI: 10.1200/JCO.2011.41.0902.
View
14.
Nahleh Z, Barlow W, Hayes D, Schott A, Gralow J, Sikov W
. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat. 2016; 158(3):485-95.
PMC: 4963434.
DOI: 10.1007/s10549-016-3889-6.
View
15.
Wang Z, Wang H, Ding X, Chen X, Shen K
. A large-cohort retrospective study of metastatic patterns and prognostic outcomes between inflammatory and non-inflammatory breast cancer. Ther Adv Med Oncol. 2020; 12:1758835920932674.
PMC: 7278308.
DOI: 10.1177/1758835920932674.
View
16.
Kheirelseid E, Jumustafa H, Miller N, Curran C, Sweeney K, Malone C
. Bilateral breast cancer: analysis of incidence, outcome, survival and disease characteristics. Breast Cancer Res Treat. 2010; 126(1):131-40.
DOI: 10.1007/s10549-010-1057-y.
View
17.
Kurtz J, Halaharvi D, Sarwar S, Cripe M
. A Case of a Bilateral Inflammatory Breast Cancer: A Case Report. Breast J. 2016; 22(3):342-346.
DOI: 10.1111/tbj.12578.
View
18.
Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B
. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res. 2009; 16(1):45-55.
PMC: 2874875.
DOI: 10.1158/1078-0432.CCR-09-1630.
View
19.
Ueno N, Fernandez J, Cristofanilli M, Overmoyer B, Rea D, Berdichevski F
. International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. J Cancer. 2018; 9(8):1437-1447.
PMC: 5929089.
DOI: 10.7150/jca.23969.
View
20.
Ravind R, Kumar P, Prabaharan S
. Inflammatory breast cancer in a previously treated case of breast cancer: a diagnostic dilemma for the clinician. BMJ Case Rep. 2016; 2016.
PMC: 4840592.
DOI: 10.1136/bcr-2016-214700.
View